Lonza Group AG (LZAGF)

605.00 -24.00 (-3.82%) At close: 03:49PM EDT

Lonza Group AG

Muenchensteinerstrasse 38
Basel 4002
Switzerland
41 61 316 81 11
https://www.lonza.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 17,834

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Wolfgang Wienand Ph.D.	Chief Executive Officer	N/A	N/A	1972
Mr. Philippe Deecke	Chief Financial Officer	N/A	N/A	1972
Ms. Maria Soler Nunez	Head of Group Operations	N/A	N/A	1969
Mr. Dirk Oehlers	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Andreas Bohrer	Group General Counsel & Company Secretary	N/A	N/A	N/A
Ms. Kim Harrelson	Head of Ethics & Compliance, ERM and Corporate Responsibility	N/A	N/A	N/A
Ms. Victoria Morgan	Head of External Communications	N/A	N/A	N/A
Ms. Jennifer Clancy	Senior Director of Global Marketing	N/A	N/A	N/A
Dr. Matthias Hofmann	Head of Corporate Environment, Health, Safety & Global Sustainability	N/A	N/A	N/A
Mr. Jean-Christophe Hyvert	President of Biologics Division	N/A	N/A	1972

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Corporate governance

Lonza Group AG’s ISS governance QualityScore as of 1 October 2024 is 1. The pillar scores are Audit: 5; Board: 1; Shareholder rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.